Abstract
BackgroundAmong patients with advanced/metastatic triple-negative breast cancer (TNBC) with high/positive programmed death-ligand 1 (PD-L1) expression, a superior survival outcome has been demonstrated with immune checkpoint inhibitors (ICIs). However, it remains...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have